EP1097147A4 - Novel angiogenesis inhibitors - Google Patents
Novel angiogenesis inhibitorsInfo
- Publication number
- EP1097147A4 EP1097147A4 EP99937204A EP99937204A EP1097147A4 EP 1097147 A4 EP1097147 A4 EP 1097147A4 EP 99937204 A EP99937204 A EP 99937204A EP 99937204 A EP99937204 A EP 99937204A EP 1097147 A4 EP1097147 A4 EP 1097147A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- angiogenesis inhibitors
- novel angiogenesis
- novel
- inhibitors
- angiogenesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9228598P | 1998-07-10 | 1998-07-10 | |
| US92285P | 1998-07-10 | ||
| GB9822700 | 1998-10-16 | ||
| GBGB9822700.2A GB9822700D0 (en) | 1998-10-16 | 1998-10-16 | Novel angiogenesis inhibitors |
| PCT/US1999/015200 WO2000002871A1 (en) | 1998-07-10 | 1999-07-06 | Novel angiogenesis inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1097147A1 EP1097147A1 (en) | 2001-05-09 |
| EP1097147A4 true EP1097147A4 (en) | 2001-11-21 |
Family
ID=26314531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP99937204A Withdrawn EP1097147A4 (en) | 1998-07-10 | 1999-07-06 | Novel angiogenesis inhibitors |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1097147A4 (en) |
| JP (1) | JP2002520324A (en) |
| AU (1) | AU747427B2 (en) |
| CA (1) | CA2336848A1 (en) |
| WO (1) | WO2000002871A1 (en) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL144910A0 (en) | 1999-04-15 | 2002-06-30 | Bristol Myers Squibb Co | Cyclic compounds and pharmaceutical compositions containing the same |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| DE10021246A1 (en) * | 2000-04-25 | 2001-10-31 | Schering Ag | New N-substituted benzamide derivatives are tyrosine kinase KDR and FLT inhibitors useful e.g. for treating tumors, psoriasis, rheumatoid arthritis, diabetic retinopathy or liver sclerosis |
| EP1347971B1 (en) | 2000-12-21 | 2006-03-01 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of tec family tyrosine kinases |
| BR0116452A (en) | 2000-12-21 | 2003-09-30 | Glaxo Group Ltd | Compound, pharmaceutical composition, use of a compound |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| US6693134B2 (en) * | 2001-05-29 | 2004-02-17 | Chemokine Therapeutics Corporation | Bicyclic aromatic chemokine receptor ligands |
| WO2003015778A1 (en) | 2001-08-17 | 2003-02-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP1503757B1 (en) | 2002-05-02 | 2007-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| SI1569907T1 (en) * | 2002-12-13 | 2016-06-30 | Ym Biosciences Australia Pty Ltd | Nicotinamide-based kinase inhibitors |
| ES2523837T3 (en) | 2003-07-18 | 2014-12-01 | Amgen Inc. | Specific binding agents to hepatocyte growth factor |
| US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
| CA2585053C (en) * | 2004-10-22 | 2011-07-12 | Janssen Pharmaceutica N.V. | Substituted n-acyl (hetero)aryl compounds as c-fms kinase inhibitors |
| JP2008521900A (en) | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | Quinolines and quinazoline analogues and their use as medicaments for the treatment of cancer |
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| AR059066A1 (en) | 2006-01-27 | 2008-03-12 | Amgen Inc | COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF) |
| ATE489380T1 (en) | 2006-02-10 | 2010-12-15 | Amgen Inc | HYDRATE FORMS OF AMG706 |
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| CA2649924C (en) | 2006-04-20 | 2014-08-19 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
| EP2021335B1 (en) | 2006-04-20 | 2011-05-25 | Janssen Pharmaceutica N.V. | Heterocyclic compounds as inhibitors of c-fms kinase |
| PE20121506A1 (en) | 2006-07-14 | 2012-11-26 | Amgen Inc | TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| CA2672438A1 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
| WO2008086014A2 (en) | 2007-01-09 | 2008-07-17 | Amgen Inc. | Bis-aryl amide derivatives useful for the treatment of cancer |
| GB0701426D0 (en) * | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
| AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
| PL2188313T3 (en) | 2007-08-21 | 2018-04-30 | Amgen, Inc. | Human c-fms antigen binding proteins |
| JO3240B1 (en) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | Inhibitors of c-fms Kinase |
| EP2250160B1 (en) | 2008-01-25 | 2015-11-11 | Millennium Pharmaceuticals, Inc. | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| EP2107054A1 (en) * | 2008-04-01 | 2009-10-07 | Università Degli Studi Di Milano - Bicocca | Antiproliferative compounds and therapeutic uses thereof |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| JP2012516329A (en) | 2009-01-30 | 2012-07-19 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Heteroaryls and their use as PI3K inhibitors |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
| US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| JP2013533318A (en) | 2010-08-11 | 2013-08-22 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Heteroaryl and uses thereof |
| JP2013536193A (en) | 2010-08-11 | 2013-09-19 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Heteroaryls and uses thereof |
| BR112013009166A2 (en) | 2010-10-13 | 2016-07-26 | Millennium Pharm Inc | heteroaryl and use thereof. |
| WO2012129344A1 (en) | 2011-03-23 | 2012-09-27 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| WO2012161879A1 (en) * | 2011-05-23 | 2012-11-29 | Merck Patent Gmbh | Thiazole derivatives |
| US9745288B2 (en) | 2011-08-16 | 2017-08-29 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| AR090263A1 (en) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
| US9303046B2 (en) | 2012-08-07 | 2016-04-05 | Janssen Pharmaceutica Nv | Process for the preparation of heterocyclic ester derivatives |
| JOP20180012A1 (en) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | Sulfonylation process using nonafluorobutanesulfonyl fluoride |
| EP2890696A1 (en) | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
| CN104860885B (en) * | 2014-02-24 | 2017-11-17 | 中国科学院上海药物研究所 | Naphthoyl aminated compounds, preparation method and use |
| AU2016205311B2 (en) | 2015-01-08 | 2022-02-17 | The Board Of Trustees Of The Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
| WO2016202935A1 (en) | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| RS62456B1 (en) | 2016-12-22 | 2021-11-30 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
| JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| MX2020002502A (en) | 2017-09-08 | 2020-07-20 | Amgen Inc | Inhibitors of kras g12c and methods of using the same. |
| US11045484B2 (en) | 2018-05-04 | 2021-06-29 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| MA52501A (en) | 2018-05-04 | 2021-03-10 | Amgen Inc | KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE |
| MA52564A (en) | 2018-05-10 | 2021-03-17 | Amgen Inc | KRAS G12C INHIBITORS FOR CANCER TREATMENT |
| EP3802535B1 (en) | 2018-06-01 | 2022-12-14 | Amgen, Inc | Kras g12c inhibitors and methods of using the same |
| AU2019284472B2 (en) | 2018-06-11 | 2024-05-30 | Amgen Inc. | KRAS G12C inhibitors for treating cancer |
| CA3100390A1 (en) | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer |
| JP7516029B2 (en) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Improved synthesis of key intermediates for KRAS G12C inhibitor compounds |
| JP7454572B2 (en) | 2018-11-19 | 2024-03-22 | アムジエン・インコーポレーテツド | KRAS G12C inhibitor and its use |
| JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
| JP2022513967A (en) | 2018-12-20 | 2022-02-09 | アムジエン・インコーポレーテツド | Heteroarylamide useful as a KIF18A inhibitor |
| KR20210106474A (en) | 2018-12-20 | 2021-08-30 | 암젠 인크 | KIF18A inhibitor |
| JP2022514268A (en) | 2018-12-20 | 2022-02-10 | アムジエン・インコーポレーテツド | KIF18A inhibitor |
| ES2997190T3 (en) | 2018-12-20 | 2025-02-14 | Amgen Inc | Heteroaryl amides useful as kif18a inhibitors |
| KR20210146287A (en) | 2019-03-01 | 2021-12-03 | 레볼루션 메디슨즈, 인크. | Bicyclic heteroaryl compounds and uses thereof |
| JP2022522778A (en) | 2019-03-01 | 2022-04-20 | レボリューション メディシンズ インコーポレイテッド | Bicyclic heterocyclyl compounds and their use |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| MX2021014126A (en) | 2019-05-21 | 2022-01-04 | Amgen Inc | FORMS IN SOLID STATE. |
| JP2022542319A (en) | 2019-08-02 | 2022-09-30 | アムジエン・インコーポレーテツド | KIF18A inhibitor |
| JP7640521B2 (en) | 2019-08-02 | 2025-03-05 | アムジエン・インコーポレーテツド | Heteroaryl amides useful as KIF18A inhibitors - Patents.com |
| MX2022001295A (en) | 2019-08-02 | 2022-02-22 | Amgen Inc | Kif18a inhibitors. |
| CN114391012A (en) | 2019-08-02 | 2022-04-22 | 美国安进公司 | Pyridine derivatives as KIF18A inhibitors |
| CA3155857A1 (en) | 2019-10-24 | 2021-04-29 | Amgen Inc. | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER |
| EP4054720A1 (en) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Ras inhibitors |
| JP2022553858A (en) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | RAS inhibitor |
| CN114867735A (en) | 2019-11-04 | 2022-08-05 | 锐新医药公司 | RAS inhibitors |
| WO2021092115A1 (en) | 2019-11-08 | 2021-05-14 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| AU2020381492A1 (en) | 2019-11-14 | 2022-05-26 | Amgen Inc. | Improved synthesis of KRAS G12C inhibitor compound |
| TW202132271A (en) | 2019-11-14 | 2021-09-01 | 美商安進公司 | Improved synthesis of kras g12c inhibitor compound |
| JP2023505100A (en) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | Covalent RAS inhibitors and uses thereof |
| JP2023509701A (en) | 2020-01-07 | 2023-03-09 | レヴォリューション・メディスンズ，インコーポレイテッド | SHP2 inhibitor dosing and methods of treating cancer |
| JP2023530351A (en) | 2020-06-18 | 2023-07-14 | レヴォリューション・メディスンズ，インコーポレイテッド | Methods of delaying, preventing and treating acquired resistance to RAS inhibitors |
| CN116209438A (en) | 2020-09-03 | 2023-06-02 | 锐新医药公司 | Treatment of malignant diseases with SHP2 mutations using SOS1 inhibitors |
| EP4214209A1 (en) | 2020-09-15 | 2023-07-26 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
| TW202241885A (en) | 2020-12-22 | 2022-11-01 | 大陸商上海齊魯銳格醫藥研發有限公司 | Sos1 inhibitors and uses thereof |
| JP2024517847A (en) | 2021-05-05 | 2024-04-23 | レボリューション メディシンズ インコーポレイテッド | RAS inhibitors |
| CN117500811A (en) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | Covalent RAS inhibitors and uses thereof |
| AR125787A1 (en) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | RAS INHIBITORS |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| EP4448526A1 (en) | 2021-12-17 | 2024-10-23 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN119136806A (en) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | Methods for treating immune-refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| TW202446388A (en) | 2023-04-14 | 2024-12-01 | 美商銳新醫藥公司 | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| US20240352038A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5104889A (en) * | 1986-08-04 | 1992-04-14 | Otsuka Pharmaceutical Factory, Inc. | Thiazole derivatives |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1497536A (en) * | 1973-12-17 | 1978-01-12 | Lilly Industries Ltd | 2-acylaminooxazoles methods for their preparation and their use |
| EP0321115B1 (en) * | 1987-12-14 | 1991-08-14 | Sawai Pharmaceutical Co., Ltd. | Carboxamide derivatives having tetrazole and thiazole rings and their use |
-
1999
- 1999-07-06 CA CA002336848A patent/CA2336848A1/en not_active Abandoned
- 1999-07-06 WO PCT/US1999/015200 patent/WO2000002871A1/en not_active Application Discontinuation
- 1999-07-06 AU AU52082/99A patent/AU747427B2/en not_active Ceased
- 1999-07-06 EP EP99937204A patent/EP1097147A4/en not_active Withdrawn
- 1999-07-06 JP JP2000559102A patent/JP2002520324A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5104889A (en) * | 1986-08-04 | 1992-04-14 | Otsuka Pharmaceutical Factory, Inc. | Thiazole derivatives |
Non-Patent Citations (5)
| Title |
|---|
| CHEM. HETEROCYCL. COMPD. (ENGL. TRANSL.) (1974), 10(7), 928-931 * |
| DATABASE BEILSTEIN [online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT/MAIN, DE; XP002176558, Database accession no. 998965 (BRN) * |
| DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002176557, retrieved from STN Database accession no. 75:35847 * |
| See also references of WO0002871A1 * |
| YAKUGAKU ZASSHI (1971), 91(4), 436-443 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU5208299A (en) | 2000-02-01 |
| JP2002520324A (en) | 2002-07-09 |
| EP1097147A1 (en) | 2001-05-09 |
| AU747427B2 (en) | 2002-05-16 |
| CA2336848A1 (en) | 2000-01-20 |
| WO2000002871A1 (en) | 2000-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1109555A4 (en) | Novel angiogenesis inhibitors | |
| EP1097147A4 (en) | Novel angiogenesis inhibitors | |
| EP0984692A4 (en) | Novel angiogenesis inhibitors | |
| EP1017682A4 (en) | Novel angiogenesis inhibitors | |
| GB9900416D0 (en) | Inhibitors | |
| PL341642A1 (en) | Novel macrolydes | |
| ZA98376B (en) | Sulfamide-metalloprotease inhibitors | |
| GB2321641B (en) | Sulfamide-metalloprotease inhibitors | |
| HUP0202076A3 (en) | Triazine angiogenesis inhibitors | |
| EP1068213A4 (en) | Novel aminoorganofunctionalsiloxanes | |
| PL345574A1 (en) | Angiogenesis inhibitors | |
| EP1153022A4 (en) | Prothease inhibitors | |
| GB9821993D0 (en) | Centraliser | |
| GB9816729D0 (en) | Substituted cyclohexylaminopyrimidines | |
| HK1039937A1 (en) | Substituted 3-thiocarbamoylpyrazoles | |
| PL347397A1 (en) | Substituted 3-aryl-pyrazoles | |
| GB2389113B (en) | B-secretase inhibitor | |
| HK1039335A1 (en) | Substituted benzoylcyclohexandiones | |
| EP1025851A4 (en) | Alpha-glucosidase inhibitor | |
| PL345866A1 (en) | Substituted cyclooctadepsipeptides | |
| GB9800681D0 (en) | Novel angiogenesis inhibitors | |
| GB9810544D0 (en) | Novel angiogenesis inhibitors | |
| GB9822700D0 (en) | Novel angiogenesis inhibitors | |
| GB9826992D0 (en) | Inhibitors | |
| GB9828697D0 (en) | Inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20010212 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
| RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 07D 263/48 A, 7C 07D 277/46 B, 7A 61K 31/42 B, 7A 61K 31/425 B, 7C 07D 413/04 B, 7C 07D 413/14 B |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20011005 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| 17Q | First examination report despatched |
Effective date: 20030918 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20040330 |